Inhibikase Therapeutics (IKT) Stock: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$1.85
-0.13 (-6.35%)
▼
5d:
-7.75%
30d:
-21.15%
90d:
-10.44%
HOLD
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $1.84, which is considered oversold relative to its 30-day fair value range of $1.98 to $2.37.
Technical Outlook: Technically, IKT is in a strong uptrend. Immediate support is located at $1.77, while resistance sits at $2.10. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: IKT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.00 (+204.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IKT is in a strong uptrend. Immediate support is located at $1.77, while resistance sits at $2.10. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: IKT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.00 (+204.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.98 -
$2.37
Company Quality Score
71/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 204.6% below Wall St target ($6.00)
- CAUTION: Bottoming setup, but lagging the sector by 33% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-7.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.98 -
$2.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.77
Resistance Level
$2.10
Current Trend
Strong Uptrend
Technical data as of
Oct 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.55
Wall Street Target
$6.00
(+204.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 12, 2026 4:51 PM ET
Data refreshes hourly during market hours. Next update: 5:51 PM
Data refreshes hourly during market hours. Next update: 5:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$572 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 51 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
29 analysts |
$371 | 46 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$306 | 67 BUY |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 74 BUY |
